



## Commercial/Healthcare Exchange PA Criteria Effective: February 10, 2022

**Prior Authorization:** Apretude

**Products Affected:** Apretude™ (cabotegravir) suspension extended-release, intramuscular

**Medication Description:** Apretude is indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Individuals must have a negative HIV-1 test prior to initiating Apretude (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP

**Covered Uses:** Pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection.

**Exclusion Criteria:**

1. Current Positive or unknown HIV Status
2. Currently receiving the following co-administered drugs for which significant decreases in cabotegravir plasma concentrations may occur due to uridine diphosphate glucuronosyltransferase (UGT1A1):
  - A. Anticonvulsants: Carbamazepine, oxcarbazepine, phenobarbital, phenytoin
  - B. Antimycobacterials: Rifampin, rifapentine

**Required Medical Information:**

1. Current HIV status
2. Current weight
3. Therapies tried and failed
4. Current medications

**Prescriber Restriction:** N/A

**Age Restriction:** > 12 years of age

**Coverage Duration:** 2 months

**Other Criteria:**

**Initial Approval Criteria**

1. **HIV Pre-Exposure Prophylaxis (PrEP)**
  - A. Patient must be deemed “ High Risk” for HIV by Physician; **AND**
  - B. Patient must weigh at least 35 kg (77 pounds); **AND**
  - C. Patient must have a negative HIV-1 test prior to initiating therapy; **AND**
  - D. The patient must meet **ONE** of the following (i. **or** ii.)
    - i. Patient has tried generic Truvada (emtricitabine/tenofovir disoproxil fumarate) for PrEP **OR**
    - ii. Patient has an intolerance or contraindication to generic Truvada(emtricitabine/tenofovir disoproxil fumarate)

January 2022



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

Page 1 of 2



according to the prescriber defined as (but not limited to):

- a. Allergic reaction
- b. Adverse drug reaction

**References:**

1. Apretude™ [package insert]. Research Triangle, NC, ViiV Healthcare Company. Updated December 2021. Accessed January 12<sup>th</sup> 2022.

**Policy Revision history**

<b>Rev #</b>	<b>Type of Change</b>	<b>Summary of Change</b>	<b>Sections Affected</b>	<b>Date</b>
1	New Policy	New Policy	All	2/10/2022